Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026609 · ClinicalTrials.gov registry record
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 3
- Enrollment target
NCT02026609 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 3 participants.
The verdict
NCT02026609 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge (OGC) and psychometric tests have been used to assess the risk for HE, but never in patients undergoing TIPS. Severe muscle loss may also predispose patients to HE. The aim of the present study is to assess if both the OGC and psychometric tests can accurately predict the development of overt HE after TIPS. Patients will be studied before TIPS and followed after TIPS for the development of HE. The role of muscle loss in favoring HE, as well as is possible reversibility after TIPS will also be investigated.
Interventions
- OTHER Oral glutamine challenge
- OTHER Psychometric Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-01-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026609
The ClinicalTrials.gov registry entry for NCT02026609 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral glutamine challenge is the first listed.
NCT02026609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026609 about?
NCT02026609 is a clinical study titled "Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)". Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge...
What is the current status of trial NCT02026609?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2015-01-27.
What interventions are being tested in trial NCT02026609?
The interventions under investigation include: Oral glutamine challenge (OTHER), Psychometric Tests (OTHER).
Who is sponsoring clinical trial NCT02026609?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.